Anti-inflammatory Medication After Cataract Surgery and Posterior Capsular Opacification

Hecht, Idan; Karesvuo, Petteri; Achiron, Asaf; Elbaz, Uri; Laine, Ilkka; Tuuminen, Raimo

doi:10.1016/j.ajo.2020.02.007

Cited by 33 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These immune cell types have been demonstrated to convert to αSMA+ myofibroblasts that are associated with the development of fibrosis [119,121]. A direct link between the inflammatory response to cataract surgery and post-cataract surgery fibrosis was shown in clinical studies which demonstrated that the use of anti-inflammatory steroid medications in cataract patients reduced PCO to levels that did not require surgical treatment to restore vision [190].…”

Section: Post-cataract Surgery Fibrosis -Posterior Capsule Opacification (Pco)mentioning

confidence: 99%

Immune responses to injury and their links to eye disease

Stepp

Menko

2021

Translational Research

111

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Post-cataract Surgery Fibrosis -Posterior Capsule Opacification (Pco)mentioning

confidence: 99%

Immune responses to injury and their links to eye disease

Stepp

Menko

2021

Translational Research

111

View full text Add to dashboard Cite

show abstract

“…Indeed, it was actually found that anti-inflammatory treatment of patients undergoing cataract removal surgery resulted in a higher number of patients developing fibrotic PCO 4 years post-surgery than subjects treated with a placebo. A recent study, however, has suggested that a combined application of non-steroidal and steroidal anti-inflammatory drugs could more effectively lower PCO incidence relative to single drug treatments (Hecht et al, 2020). Moreover, Symonds et al (Symonds et al, 2006) demonstrated that the steroid dexamethasone, which is routinely administered to patients undergoing cataract surgery, improves cell survival and increases collagen type I synthesis in a rat lens explant model of J o u r n a l P r e -p r o o f PCO.…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Posterior capsule opacification: What's in the bag?

Wormstone

Smith

et al. 2021

Progress in Retinal and Eye Research

120

102

View full text Add to dashboard Cite

show abstract

“…Clinical studies can be further used to determine the effectiveness of treatments although there are a limited number of effective therapeutics to date. Hecht [127] presented a retrospective cohort study of 13,368 patients to examine the impact of steroids and NSAID therapy on PCO rates. The mean follow-up was 22.8 ± 15.7 months; a sufficient time period for PCO to develop.…”

Section: Investigating Potential Therapeutic Interventionsmentioning

confidence: 99%

“…• Identifying risk factors [47,89] • Investigation of therapeutic interventions [127] • Investigation of intraocular lenses [11,12,53,[68][69][70]121] • Surgical technique evaluation [58,125]…”

Section: Model Type Tissue Donors Application Referencesmentioning

confidence: 99%

Factors Affecting Posterior Capsule Opacification in the Development of Intraocular Lens Materials

Cooksley

Lacey²,

Dymond

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

Posterior capsule opacification (PCO) is the most common complication arising from the corrective surgery used to treat cataract patients. PCO arises when lens epithelial cells (LEC) residing in the capsular bag post-surgery undergo hyper-proliferation and transdifferentiation into myofibroblasts, migrating from the posterior capsule over the visual axis of the newly implanted intraocular lens (IOL). The developmental pathways underlying PCO are yet to be fully understood and the current literature is contradictory regarding the impact of the recognised risk factors of PCO. The aim of this review is firstly to collate the known biochemical pathways that lead to PCO development, providing an up-to-date chronological overview from surgery to established PCO formation. Secondly, the risk factors of PCO are evaluated, focussing on the impact of IOLs’ properties. Finally, the latest experimental model designs used in PCO research are discussed to demonstrate the ongoing development of clinical PCO models, the efficacy of newly developed IOL technology, and potential therapeutic interventions. This review will contribute to current PCO literature by presenting an updated overview of the known developmental pathways of PCO, an evaluation of the impact of the risk factors underlying its development, and the latest experimental models used to investigate PCO. Furthermore, the review should provide developmental routes for research into the investigation of potential therapeutic interventions and improvements in IOL design in the aid of preventing PCO for new and existing patients.

show abstract

Anti-inflammatory Medication After Cataract Surgery and Posterior Capsular Opacification

Cited by 33 publications

References 32 publications

Immune responses to injury and their links to eye disease

Immune responses to injury and their links to eye disease

Posterior capsule opacification: What's in the bag?

Factors Affecting Posterior Capsule Opacification in the Development of Intraocular Lens Materials

Contact Info

Product

Resources

About